
05 Aug 2026
Reckitt Announces U.S. FDA Approval of Mucinex 12HR Cold & Fever Multi-Symptom, the First OTC Innovation in the Cold & Flu Category in 14 Years
Company’s First New Drug Approval Addresses #1 Unmet Need for Long-Lasting Symptom Relief*
Reckitt net annual revenue in 2025
driving over 80% of Core net revenue
employees operating in 80 countries
Reckitt products sold each day
Discover how Reckitt’s people and brands are making a difference every day. From breakthrough innovations to community impact, explore the stories that drive our mission.
All newsOur journey to sustainable growth is well on track, and now we’re seeing the results.
Learn moreImproving access to health and hygiene is the foundation of our business. See our reports and progress.
Learn more


